|
US6143746A
(en)
|
1994-01-21 |
2000-11-07 |
Icos Corporation |
Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
|
|
GB9514465D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
GB9511220D0
(en)
*
|
1995-06-02 |
1995-07-26 |
Glaxo Group Ltd |
Solid dispersions
|
|
US6060477A
(en)
|
1995-06-07 |
2000-05-09 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
|
|
US6046216A
(en)
|
1995-06-07 |
2000-04-04 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
|
|
US6232312B1
(en)
|
1995-06-07 |
2001-05-15 |
Cell Pathways, Inc. |
Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
|
|
US5874440A
(en)
|
1995-06-07 |
1999-02-23 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
|
|
US6262059B1
(en)
|
1995-06-07 |
2001-07-17 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with quinazoline derivatives
|
|
US6200980B1
(en)
|
1995-06-07 |
2001-03-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl purinone derivatives
|
|
GB9514464D0
(en)
*
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Medicaments
|
|
GB9514473D0
(en)
|
1995-07-14 |
1995-09-13 |
Glaxo Lab Sa |
Chemical compounds
|
|
BR9709230A
(pt)
*
|
1996-05-10 |
1999-08-10 |
Icos Corp |
Composto
|
|
US5958926A
(en)
*
|
1996-11-01 |
1999-09-28 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
|
US6331543B1
(en)
*
|
1996-11-01 |
2001-12-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
|
|
US6071934A
(en)
|
1997-03-25 |
2000-06-06 |
Cell Pathways, Inc. |
Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
|
|
WO1998058633A2
(en)
|
1997-06-23 |
1998-12-30 |
Queen's University At Kingston |
Microdose therapy of vascular conditions by no donors
|
|
US6403597B1
(en)
*
|
1997-10-28 |
2002-06-11 |
Vivus, Inc. |
Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
|
|
US6410584B1
(en)
|
1998-01-14 |
2002-06-25 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells with indole derivatives
|
|
US6046199A
(en)
*
|
1998-01-14 |
2000-04-04 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
|
|
US6268372B1
(en)
|
1998-09-11 |
2001-07-31 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
|
|
US6326379B1
(en)
|
1998-09-16 |
2001-12-04 |
Bristol-Myers Squibb Co. |
Fused pyridine inhibitors of cGMP phosphodiesterase
|
|
IL132406A0
(en)
*
|
1998-10-21 |
2001-03-19 |
Pfizer Prod Inc |
Treatment of bph with cgmp elevators
|
|
US6133271A
(en)
|
1998-11-19 |
2000-10-17 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
|
|
US6187779B1
(en)
|
1998-11-20 |
2001-02-13 |
Cell Pathways, Inc. |
Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
|
|
US6348032B1
(en)
|
1998-11-23 |
2002-02-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with benzimidazole derivatives
|
|
US6211220B1
(en)
|
1998-11-23 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
|
|
US6211177B1
(en)
|
1998-11-24 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
|
|
US6420410B1
(en)
|
1998-11-24 |
2002-07-16 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
|
|
US6486155B1
(en)
|
1998-11-24 |
2002-11-26 |
Cell Pathways Inc |
Method of inhibiting neoplastic cells with isoquinoline derivatives
|
|
US6358992B1
(en)
|
1998-11-25 |
2002-03-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with indole derivatives
|
|
ES2213004T3
(es)
|
1999-03-24 |
2004-08-16 |
Harbor Branch Oceanographic Institution, Inc. |
Usos antiinflamatorios de manzaminas.
|
|
US6943166B1
(en)
*
|
1999-04-30 |
2005-09-13 |
Lilly Icos Llc. |
Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
|
|
MXPA00003997A
(es)
*
|
1999-04-30 |
2002-03-08 |
Lilly Icos Llc |
Articulos de fabricacion.
|
|
US6451807B1
(en)
|
1999-04-30 |
2002-09-17 |
Lilly Icos, Llc. |
Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
|
|
US7235625B2
(en)
|
1999-06-29 |
2007-06-26 |
Palatin Technologies, Inc. |
Multiple agent therapy for sexual dysfunction
|
|
KR100738861B1
(ko)
*
|
1999-08-03 |
2007-07-16 |
릴리 아이코스 엘엘씨 |
베타-카르볼린 약학 조성물
|
|
US6821975B1
(en)
|
1999-08-03 |
2004-11-23 |
Lilly Icos Llc |
Beta-carboline drug products
|
|
CZ20021151A3
(cs)
|
1999-10-11 |
2003-03-12 |
Pfizer Inc. |
5-(2-substituovaný-5-heterocyklylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]-pyrimidin-7-ony jako inhibitory fosfodiesterasy
|
|
TW200400821A
(en)
*
|
1999-11-02 |
2004-01-16 |
Pfizer |
Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
|
|
US6562830B1
(en)
|
1999-11-09 |
2003-05-13 |
Cell Pathways, Inc. |
Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
|
|
US6376489B1
(en)
*
|
1999-12-23 |
2002-04-23 |
Icos Corporation |
Cyclic AMP-specific phosphodiesterase inhibitors
|
|
US20020013327A1
(en)
*
|
2000-04-18 |
2002-01-31 |
Lee Andrew G. |
Compositions and methods for treating female sexual dysfunction
|
|
JP2004500425A
(ja)
|
2000-04-19 |
2004-01-08 |
リリー アイコス リミテッド ライアビリティ カンパニー |
パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用
|
|
UA74826C2
(en)
*
|
2000-05-17 |
2006-02-15 |
Ortho Mcneil Pharm Inc |
?-carboline derivatives as phosphodiesterase inhibitors
|
|
UA72611C2
(uk)
*
|
2000-05-17 |
2005-03-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
|
|
EP1289989A2
(en)
|
2000-06-07 |
2003-03-12 |
Lilly Icos LLC |
Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
|
|
MXPA02012470A
(es)
*
|
2000-06-23 |
2004-01-26 |
Lilly Icos Llc |
Inhibidores de fosfodiesterasa especificos para gmp ciclico.
|
|
ES2269401T3
(es)
*
|
2000-06-23 |
2007-04-01 |
Lilly Icos Llc |
Derivados de piracino(1'2':1,6)pirido(3,4-b)indol.
|
|
AU2001266575A1
(en)
*
|
2000-06-26 |
2002-01-08 |
Lilly Icos Llc |
Chemical compounds
|
|
US7176228B2
(en)
*
|
2000-07-24 |
2007-02-13 |
Bayer Cropscience Ag |
Pyrazole biphenylcarboxamides
|
|
US7034027B2
(en)
|
2000-08-02 |
2006-04-25 |
Lilly Icos Llc |
Fused heterocyclic derivatives as phosphodiesterase inhibitors
|
|
US6503894B1
(en)
*
|
2000-08-30 |
2003-01-07 |
Unimed Pharmaceuticals, Inc. |
Pharmaceutical composition and method for treating hypogonadism
|
|
US20040092494A9
(en)
*
|
2000-08-30 |
2004-05-13 |
Dudley Robert E. |
Method of increasing testosterone and related steroid concentrations in women
|
|
US6821978B2
(en)
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
|
US6962918B2
(en)
|
2000-10-02 |
2005-11-08 |
Lilly Icos Llc. |
Hexahydropyrazino[1'2';1,6]pyrido[3,4-b]indole-1,4-diones for the treatment of cardiovascular disorders and erectile dysfunction
|
|
AU2002213419A1
(en)
|
2000-10-02 |
2002-04-15 |
Lilly Icos Llc |
Condensed pyridoindole derivatives
|
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
|
EP1211313A3
(en)
*
|
2000-11-01 |
2003-04-23 |
Pfizer Limited |
Modulation of PDE11A activity
|
|
US6828473B2
(en)
|
2000-11-01 |
2004-12-07 |
Pfizer Inc. |
Modulation of PDE11A activity
|
|
CA2427573C
(en)
*
|
2000-11-06 |
2008-10-07 |
Lilly Icos Llc |
Indole derivatives as pde5-inhibitors
|
|
JP4216606B2
(ja)
*
|
2001-04-25 |
2009-01-28 |
リリー アイコス リミテッド ライアビリティ カンパニー |
化学化合物
|
|
FR2824829B1
(fr)
*
|
2001-05-16 |
2005-06-03 |
Macef |
Nouveaux derives de dihydroimidazo [5,1-a]-beta-carboline, leur procede de preparation et leur application a titre de medicament
|
|
JP4217605B2
(ja)
*
|
2001-06-05 |
2009-02-04 |
リリー アイコス リミテッド ライアビリティ カンパニー |
ピラジノ［１’，２’：１，６］ピリド［３，４−ｂ］インドール−１，４−ジオン誘導体
|
|
WO2002098428A1
(en)
*
|
2001-06-05 |
2002-12-12 |
Lilly Icos Llc |
Tetracyclic compounds as pde5-inhibitors
|
|
CA2445460A1
(en)
|
2001-06-05 |
2002-12-12 |
Lilly Icos Llc |
Carboline derivatives as pde-5 inhibitors
|
|
DE60213798T2
(de)
|
2001-06-21 |
2007-08-16 |
Lilly Icos Llc, Wilmington |
Carbolinderivate als pdev inhibitoren
|
|
UA78974C2
(en)
|
2001-10-20 |
2007-05-10 |
Boehringer Ingelheim Pharma |
Use of flibanserin for treating disorders of sexual desire
|
|
US10675280B2
(en)
|
2001-10-20 |
2020-06-09 |
Sprout Pharmaceuticals, Inc. |
Treating sexual desire disorders with flibanserin
|
|
MXPA04004370A
(es)
*
|
2001-11-09 |
2004-08-11 |
Schering Corp |
Derivados policiclicos de guanina inhibidores de fosfodiesterasa v.
|
|
DE60221425T2
(de)
*
|
2001-11-14 |
2008-06-26 |
Ortho-Mcneil Pharmaceutical, Inc. |
Substituierte tetrazyklische pyrrolochinolonderivate als phosphodiesterase-inhibitoren
|
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
|
US7208516B2
(en)
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
|
US7276529B2
(en)
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
DE10220570A1
(de)
|
2002-05-08 |
2003-11-20 |
Bayer Ag |
Carbamat-substituierte Pyrazolopyridine
|
|
CA2485984A1
(en)
*
|
2002-05-23 |
2003-12-04 |
Pfizer Inc. |
Pharmaceutical combination of pde5 inhibitors with ace inhibitors
|
|
EP1719772A1
(en)
|
2002-05-31 |
2006-11-08 |
Schering Corporation |
Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
|
|
GB0214784D0
(en)
*
|
2002-06-26 |
2002-08-07 |
Pfizer Ltd |
Novel combination
|
|
AU2003256539B2
(en)
*
|
2002-07-31 |
2010-03-04 |
Icos Corporation |
Modified pictet-spengler reaction and products prepared therefrom
|
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
|
JP2006511606A
(ja)
|
2002-12-13 |
2006-04-06 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
下部尿路症状を治療するα−２−δリガンド
|
|
AU2004226353A1
(en)
|
2003-04-01 |
2004-10-14 |
Laboratoires Serono Sa |
Inhibitors of phosphodiesterases in infertility
|
|
EP1620437B1
(en)
|
2003-04-29 |
2009-06-17 |
Pfizer Limited |
5,7-diaminopyrazolo¬4,3-d pyrimidines useful in the traetment of hypertension
|
|
CN1791429A
(zh)
*
|
2003-05-22 |
2006-06-21 |
奥坦纳医药公司 |
包含pde4抑制剂和pde5抑制剂的组合物
|
|
PT1644021E
(pt)
|
2003-06-13 |
2013-01-30 |
Ironwood Pharmaceuticals Inc |
Métodos e composições para o tratamento de distúrbios gastrointestinais
|
|
WO2004113300A1
(ja)
*
|
2003-06-23 |
2004-12-29 |
Ono Pharmaceutical Co., Ltd. |
新規三環性複素環化合物
|
|
US7291640B2
(en)
|
2003-09-22 |
2007-11-06 |
Pfizer Inc. |
Substituted triazole derivatives as oxytocin antagonists
|
|
US7572799B2
(en)
|
2003-11-24 |
2009-08-11 |
Pfizer Inc |
Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
|
|
WO2005058280A2
(en)
*
|
2003-12-12 |
2005-06-30 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
|
|
WO2005068464A2
(en)
*
|
2003-12-15 |
2005-07-28 |
Cadila Healthcare Limited |
Process for preparing tadalafil and its intermediates
|
|
WO2005079808A1
(en)
|
2004-01-22 |
2005-09-01 |
Pfizer Limited |
Triazole derivatives which inhibit vasopressin antagonistic activity
|
|
US7649002B2
(en)
|
2004-02-04 |
2010-01-19 |
Pfizer Inc |
(3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
|
|
JP2007530563A
(ja)
*
|
2004-03-22 |
2007-11-01 |
ミオゲン インコーポレイティッド |
（ｓ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
|
|
JP2007530566A
(ja)
*
|
2004-03-22 |
2007-11-01 |
ミオゲン インコーポレイティッド |
（ｒ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
|
|
ES2317209T3
(es)
|
2004-04-07 |
2009-04-16 |
Pfizer Inc. |
Pirazolo(4,3-) pirimidinas.
|
|
WO2005116030A1
(en)
*
|
2004-05-31 |
2005-12-08 |
Matrix Laboratories Ltd |
A process for the preparation of tadalafil
|
|
CA2572179A1
(en)
*
|
2004-06-23 |
2006-01-19 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of pde-iii mediated diseases
|
|
EP1786428B1
(en)
|
2004-08-17 |
2012-05-16 |
The Johns Hopkins University |
Pde5 inhibitor compositions and methods for treating cardiac indications
|
|
EP1804582A4
(en)
*
|
2004-10-28 |
2009-12-09 |
Reddys Lab Ltd Dr |
POLYMORPH SHAPES OF TADALAFIL
|
|
KR20070072891A
(ko)
*
|
2004-11-02 |
2007-07-06 |
테바 파마슈티컬 인더스트리즈 리미티드 |
타달라필 결정형 및 이의 제조 방법
|
|
AR051780A1
(es)
*
|
2004-11-29 |
2007-02-07 |
Japan Tobacco Inc |
Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
|
|
PL1829874T3
(pl)
|
2004-12-22 |
2014-07-31 |
Ono Pharmaceutical Co |
Tricykliczny związek i jego zastosowanie
|
|
EP1851223A1
(en)
*
|
2005-02-25 |
2007-11-07 |
Teva Pharmaceutical Industries Ltd |
Process of purifying tadalafil
|
|
WO2006091974A1
(en)
|
2005-02-25 |
2006-08-31 |
Teva Pharmaceutical Industries Ltd. |
Tadalafil having a large particle size and a process for preparation thereof
|
|
CA2596667A1
(en)
*
|
2005-02-25 |
2006-08-31 |
Teva Pharmaceutical Industries Ltd. |
Process of synthesizing tadalafil
|
|
US20070088012A1
(en)
*
|
2005-04-08 |
2007-04-19 |
Woun Seo |
Method of treating or preventing type-2 diabetes
|
|
DE06750162T1
(de)
*
|
2005-04-12 |
2007-07-05 |
Teva Pharmaceutical Industries Ltd. |
Herstellung von Tadalafil-Zwischenprodukten
|
|
US8648100B2
(en)
|
2005-04-19 |
2014-02-11 |
Takeda Gmbh |
Roflumilast for the treatment of pulmonary hypertension
|
|
US8506934B2
(en)
|
2005-04-29 |
2013-08-13 |
Robert I. Henkin |
Methods for detection of biological substances
|
|
NZ564187A
(en)
|
2005-05-12 |
2010-03-26 |
Pfizer |
Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
|
|
US20070010525A1
(en)
*
|
2005-06-27 |
2007-01-11 |
Meyer Jackson |
Method and compositions for modulating neuropeptide hormone secretion
|
|
US7863274B2
(en)
*
|
2005-07-29 |
2011-01-04 |
Concert Pharmaceuticals Inc. |
Deuterium enriched analogues of tadalafil as PDE5 inhibitors
|
|
BRPI0615972A2
(pt)
*
|
2005-07-29 |
2011-05-31 |
Concert Pharmaceuticals Inc |
composto isolado, mistura, composição, item de manufatura, uso de um composto, método para determinar a concentração do composto em uma amostra biológica, kit de diagnóstico e método para avaliar a estabilidade metabólica de um composto
|
|
US8227476B2
(en)
|
2005-08-03 |
2012-07-24 |
Sprout Pharmaceuticals, Inc. |
Use of flibanserin in the treatment of obesity
|
|
WO2007025177A2
(en)
|
2005-08-26 |
2007-03-01 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
EP2258359A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation with sabcomelin
|
|
JP2009507925A
(ja)
*
|
2005-09-13 |
2009-02-26 |
エラン ファーマ インターナショナル リミテッド |
ナノ粒子タダラフィル製剤
|
|
SI2450041T1
(sl)
|
2005-10-12 |
2019-02-28 |
Unimed Pharmaceuticals, Llc |
Izboljšan testosteronski gel za uporabo pri zdravljenju hipogonadizma
|
|
EP2377530A3
(en)
|
2005-10-21 |
2012-06-20 |
Braincells, Inc. |
Modulation of neurogenesis by PDE inhibition
|
|
CA2626134C
(en)
|
2005-10-29 |
2013-12-24 |
Boehringer Ingelheim International Gmbh |
Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
|
|
EP1942879A1
(en)
|
2005-10-31 |
2008-07-16 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
WO2007100387A2
(en)
*
|
2005-11-03 |
2007-09-07 |
Dr. Reddy's Laboratories Ltd. |
Process for preparing tadalafil
|
|
BRPI0618643A2
(pt)
|
2005-11-09 |
2011-09-06 |
Combinatorx Inc |
composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso
|
|
US7202229B1
(en)
*
|
2005-12-30 |
2007-04-10 |
Alan James Group, Llc. |
Aspirin formulation for cardiovascular health
|
|
US7201929B1
(en)
*
|
2005-12-30 |
2007-04-10 |
Alan James Group, Llc. |
Aspirin formulation for cardiovascular health
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
CA2643199A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
US20100216734A1
(en)
*
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
EP2004644A1
(en)
*
|
2006-03-24 |
2008-12-24 |
Glenmark Pharmaceuticals Limited |
Process for the preparation of tadalafil
|
|
US20080027072A1
(en)
*
|
2006-04-20 |
2008-01-31 |
Ampla Pharmaceuticals, Inc. |
Potentiation of MC4 receptor activity
|
|
EP2021000A2
(en)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
MX2008014320A
(es)
*
|
2006-05-09 |
2009-03-25 |
Braincells Inc |
Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
|
|
US20100009983A1
(en)
*
|
2006-05-09 |
2010-01-14 |
Braincells, Inc. |
5 ht receptor mediated neurogenesis
|
|
US20090291958A1
(en)
*
|
2006-06-08 |
2009-11-26 |
Auspex Pharmaceuticals, Inc. |
Substituted PDE5 inhibitors
|
|
DE602007004615D1
(de)
|
2006-06-30 |
2010-03-18 |
Boehringer Ingelheim Pharma |
Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
|
|
WO2008005039A1
(en)
*
|
2006-07-07 |
2008-01-10 |
Teva Pharmaceutical Industries Ltd. |
Solid compositions comprising tadalafil and at least one carrier
|
|
DE602007005139D1
(de)
|
2006-07-21 |
2010-04-15 |
Novartis Ag |
Formulierungen für benzimidazolylpyridylether
|
|
AU2007286288A1
(en)
|
2006-08-14 |
2008-02-21 |
Boehringer Ingelheim International Gmbh |
Formulations of flibanserin and method for manufacturing the same
|
|
CN104721168A
(zh)
|
2006-08-25 |
2015-06-24 |
贝林格尔·英格海姆国际有限公司 |
控制释放系统及其制造方法
|
|
AR062501A1
(es)
*
|
2006-08-29 |
2008-11-12 |
Actelion Pharmaceuticals Ltd |
Composiciones terapeuticas
|
|
BRPI0716604A2
(pt)
*
|
2006-09-08 |
2013-04-09 |
Braincells Inc |
combinaÇÕes contendo um derivado de 4-acilaminopiridina
|
|
AU2007299920A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Braincells, Inc. |
PPAR Mediated Modulation of Neurogenesis
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
EP2101777B1
(en)
|
2006-12-12 |
2015-05-20 |
Gilead Sciences, Inc. |
Composition for treating a pulmonary hypertension
|
|
WO2008095136A2
(en)
|
2007-01-31 |
2008-08-07 |
Henkin Robert I |
Methods for detection of biological substances
|
|
EP2120570B1
(en)
*
|
2007-02-12 |
2012-05-16 |
DMI Biosciences, Inc. |
Treatment of comorbid premature ejaculation and erectile dysfunction
|
|
CA2677691C
(en)
*
|
2007-02-12 |
2012-07-31 |
David Bar-Or |
Reducing side effects of tramadol
|
|
WO2008103470A2
(en)
*
|
2007-02-21 |
2008-08-28 |
Trustees Of Columbia University In The City Of New York |
Oncogenic-ras-signal dependent lethal compounds
|
|
RU2456989C2
(ru)
*
|
2007-04-25 |
2012-07-27 |
Тева Фармасьютикал Индастриес Лтд. |
Твердые лекарственные формы, содержащие тадалафил
|
|
FR2916200A1
(fr)
*
|
2007-05-18 |
2008-11-21 |
Fourtillan Snc |
Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
|
|
DE102007028869A1
(de)
*
|
2007-06-22 |
2008-12-24 |
Ratiopharm Gmbh |
Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
|
|
PT2170880E
(pt)
*
|
2007-06-29 |
2012-10-29 |
Ranbaxy Lab Ltd |
Processo para a preparação de intermediários de compostos tetracíclicos
|
|
EP2033962A1
(en)
*
|
2007-08-22 |
2009-03-11 |
4Sc Ag |
Tetracyclic indolopyridines as EG5 inhibitors
|
|
UY31335A1
(es)
|
2007-09-12 |
2009-04-30 |
|
Tratamiento de sintomas vasomotores
|
|
WO2009091777A1
(en)
*
|
2008-01-15 |
2009-07-23 |
Forest Laboratories Holdings Limited |
Nebivolol in the treatment of sexual dysfunction
|
|
ITMI20080285A1
(it)
*
|
2008-02-22 |
2009-08-23 |
Endura Spa |
Procedimento per la preparazione di esteri di acidi tetraidro-1h-betacarbolin-3-carbossilici
|
|
EP2107059A1
(en)
*
|
2008-03-31 |
2009-10-07 |
LEK Pharmaceuticals D.D. |
Conversion of tryptophan into ß-carboline derivatives
|
|
PL385356A1
(pl)
|
2008-06-03 |
2009-12-07 |
Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna |
Sposób wytwarzania tadalafilu
|
|
US8580801B2
(en)
|
2008-07-23 |
2013-11-12 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
|
EP2181997A1
(en)
|
2008-10-30 |
2010-05-05 |
Chemo Ibérica, S.A. |
A process for the preparation of tadalafil
|
|
DE102008063992A1
(de)
|
2008-12-19 |
2010-09-02 |
Lerner, Zinoviy, Dipl.-Ing. |
Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
|
|
EP2379076B1
(en)
|
2008-12-23 |
2014-11-12 |
The Trustees of Columbia University in the City of New York |
Phosphodiesterase inhibitors and uses thereof
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
EP2400848A4
(en)
|
2009-02-26 |
2012-07-25 |
Thar Pharmaceuticals Inc |
CRYSTALLIZATION OF PHARMACEUTICAL COMPOUNDS
|
|
GB0903493D0
(en)
|
2009-02-27 |
2009-04-08 |
Vantia Ltd |
New compounds
|
|
DE102009033396A1
(de)
|
2009-07-16 |
2011-01-20 |
Ratiopharm Gmbh |
Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
|
|
UY33041A
(es)
|
2009-11-27 |
2011-06-30 |
Bayer Schering Pharma Aktienegesellschaft |
Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
|
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
|
EP2556820A4
(en)
|
2010-04-05 |
2015-01-21 |
Sk Chemicals Co Ltd |
COMPOSITION CONTAINING PDE5 INHIBITOR FOR MITIGATION OF SKIN WRINKLES
|
|
DE102010021637A1
(de)
|
2010-05-26 |
2011-12-01 |
Bayer Schering Pharma Aktiengesellschaft |
Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
|
|
KR20130069855A
(ko)
|
2010-10-15 |
2013-06-26 |
길리애드 사이언시즈, 인코포레이티드 |
폐 고혈압 치료의 조성물 및 방법
|
|
WO2012107092A1
(en)
|
2011-02-10 |
2012-08-16 |
Synthon Bv |
Pharmaceutical composition comprising tadalafil and a cyclodextrin
|
|
EP2672959A1
(en)
|
2011-02-10 |
2013-12-18 |
Synthon BV |
Granulated composition comprising tadalafil and a disintegrant
|
|
RU2013141446A
(ru)
|
2011-02-10 |
2015-03-20 |
Синтон Бв |
Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
|
|
JP5816704B2
(ja)
|
2011-02-10 |
2015-11-18 |
インテルキム、ソシエダッド アノニマ |
テトラヒドロ−β−カルボリンから誘導される化合物を得る方法
|
|
US20120123124A1
(en)
*
|
2011-04-22 |
2012-05-17 |
Drug Process Licensing Associates, LLC |
Manufacturing process for Tadalafil from racemic or L-tryptophan
|
|
CN102180876B
(zh)
*
|
2011-05-28 |
2016-05-18 |
浙江华海药业股份有限公司 |
一种他达那非晶型i的制备方法
|
|
EP2535049A1
(en)
|
2011-06-17 |
2012-12-19 |
Proyecto de Biomedicina Cima, S.L. |
Tadalafil for the treatment of dementia
|
|
CN102367253B
(zh)
*
|
2011-09-20 |
2016-04-06 |
浙江华海药业股份有限公司 |
一种制备他达拉非晶型a的方法
|
|
US9402877B2
(en)
|
2011-11-04 |
2016-08-02 |
Xion Pharmaceuticals Corporation |
Methods and compositions for oral administration of melanocortin receptor agonist compounds
|
|
US20150119399A1
(en)
|
2012-01-10 |
2015-04-30 |
President And Fellows Of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
|
WO2013109738A1
(en)
|
2012-01-17 |
2013-07-25 |
The Trustees Of Columbia University In The City Of New York |
Novel phosphodiesterase inhibitors and uses thereof
|
|
WO2013109225A1
(en)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Pharmaceutical tablet formulations comprising ceftibuten
|
|
WO2014092661A1
(en)
|
2012-01-18 |
2014-06-19 |
Mahmut Bilgic |
Particulate formulations of tadalafil in effervescent form
|
|
WO2013109223A1
(en)
|
2012-01-18 |
2013-07-25 |
Mahmut Bilgic |
Particulate formulations of tadalafil in effervescent form
|
|
IN2014MN01706A
(ca)
|
2012-02-28 |
2015-05-29 |
Seoul Pharma Co Ltd |
|
|
US20150297601A1
(en)
|
2012-10-05 |
2015-10-22 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
|
CN105025900B
(zh)
|
2012-12-04 |
2018-11-02 |
株式会社阿丽浱欧 |
包含5型磷酸二酯酶抑制剂的神经细胞的细胞凋亡抑制用组合物
|
|
KR101953735B1
(ko)
|
2012-12-14 |
2019-03-04 |
한미약품 주식회사 |
포스포다이에스터라제-5 억제제를 포함하는 츄정
|
|
US9789126B2
(en)
|
2012-12-21 |
2017-10-17 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating calcific aortic valve stenosis
|
|
SG11201506211RA
(en)
|
2013-02-21 |
2015-09-29 |
Adverio Pharma Gmbh |
Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
|
|
CN103232451A
(zh)
*
|
2013-05-14 |
2013-08-07 |
张家港威胜生物医药有限公司 |
一种他达那非的简易制备工艺
|
|
EP3022205B1
(en)
|
2013-07-17 |
2020-02-05 |
The Trustees of Columbia University in the City of New York |
Novel phosphodiesterase inhibitors and uses thereof
|
|
WO2015089105A1
(en)
|
2013-12-09 |
2015-06-18 |
Respira Therapeutics, Inc. |
Pde5 inhibitor powder formulations and methods relating thereto
|
|
WO2015126944A1
(en)
|
2014-02-18 |
2015-08-27 |
Henkin Robert I |
Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
|
|
AR099416A1
(es)
|
2014-02-28 |
2016-07-20 |
Lilly Co Eli |
Terapia combinada para la hipertensión resistente
|
|
WO2015200177A1
(en)
|
2014-06-23 |
2015-12-30 |
Celgene Corporation |
Apremilast for the treatment of a liver disease or a liver function abnormality
|
|
EP2962684A1
(en)
|
2014-06-30 |
2016-01-06 |
Sanovel Ilac Sanayi ve Ticaret A.S. |
Orally disintegrating formulations of tadalafil
|
|
ES2784251T3
(es)
|
2014-06-30 |
2020-09-23 |
Montero Gida Sanayi Ve Ticaret As |
Formulaciones de disgregación por vía oral de tadalafilo
|
|
CN104086546B
(zh)
*
|
2014-07-14 |
2016-08-17 |
福建广生堂药业股份有限公司 |
他达拉非的药用酸盐及其制备方法
|
|
EP3466951B1
(en)
|
2014-07-23 |
2022-01-19 |
KRKA, d.d., Novo mesto |
A process for the preparation of cgmp-phosphodiesterase inhibitor and oral pharmaceutical formulation comprising tadalafil co-precipitates
|
|
KR101645652B1
(ko)
|
2014-11-03 |
2016-08-08 |
(주)퓨젠바이오농업회사법인 |
세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
|
|
CA2987109C
(en)
|
2015-06-26 |
2020-07-07 |
Chongqing University of Arts and Sciences |
6-(benzo[d][1,3]dioxol-5-yl)-2-substituted-2,3,12,12a-tetrahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4(6h,7h)-dione derivatives as phosphodiesterase type-5 inhibitors
|
|
CN105541840B
(zh)
*
|
2015-12-31 |
2017-12-05 |
湖南千金湘江药业股份有限公司 |
关键中间体及其合成方法和在制备他达拉非方面的应用
|
|
CN105541835B
(zh)
*
|
2015-12-31 |
2017-12-05 |
湖南千金湘江药业股份有限公司 |
顺式四氢咔啉中间体及其合成方法和在制备他达拉非方面的应用
|
|
CA3046025A1
(en)
|
2016-12-14 |
2018-06-21 |
Respira Therapeutics, Inc. |
Methods and compositions for treatment of pulmonary hypertension and other lung disorders
|
|
CN106977516B
(zh)
*
|
2017-03-02 |
2019-06-18 |
山东裕欣药业有限公司 |
一种他达拉非的制备方法
|
|
JP2022526621A
(ja)
|
2019-04-10 |
2022-05-25 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
心血管機能障害の性別依存性処置のための方法及び材料
|
|
RU2692764C1
(ru)
|
2019-04-26 |
2019-06-27 |
Общество с ограниченной ответственностью "Балтфарма" |
Способ получения тадалафила
|
|
CN111995658B
(zh)
*
|
2019-05-27 |
2022-08-02 |
首都医科大学 |
Ldv修饰的五环哌嗪二酮及其制备和应用
|
|
MX2021015425A
(es)
|
2019-07-15 |
2022-02-21 |
Biolab Sanus Farmaceutica Ltda |
Estereoisomeros del compuesto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hi droxipropano-2-il)-1-(1h-indol-3-il)-6,7-dihidro-3h-oxazol[3,4-a] pirazina-5,8-diona y su uso como antitumoral y inhibidor de la enzima fosfodiesterasa.
|
|
CN110606847A
(zh)
*
|
2019-07-30 |
2019-12-24 |
中国医药集团总公司四川抗菌素工业研究所 |
一种他达拉非顺式中间体的制备方法及其应用
|
|
US11590209B2
(en)
|
2020-01-21 |
2023-02-28 |
Palatin Technologies, Inc. |
Use of bremelanotide in patients with controlled hypertension
|
|
US12569493B2
(en)
|
2020-03-24 |
2026-03-10 |
Cyrano Therapeutics Inc. |
Treatment of chemosensory dysfunction from a coronavirus infection
|
|
WO2021245192A1
(en)
|
2020-06-04 |
2021-12-09 |
Topadur Pharma Ag |
Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
|
|
CN120641103A
(zh)
|
2023-01-25 |
2025-09-12 |
阿丽派欧株式会社 |
包含5型磷酸二酯酶抑制剂作为有效成分用于预防或治疗创伤后应激障碍的组合物
|
|
AU2024220563A1
(en)
|
2023-02-16 |
2025-08-14 |
University Of Rochester |
Improving glymphatic-lymphatic efflux
|
|
CN116715667A
(zh)
*
|
2023-06-20 |
2023-09-08 |
常州制药厂有限公司 |
一种他达拉非新晶型b及其制备方法
|
|
EP4684777A1
(en)
|
2024-07-24 |
2026-01-28 |
Adalvo Limited |
A fixed-dose pharmaceutical composition comprising (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid and (6r,12ar)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino{1',2:1,6]pyrido[3,4-b]indole-1,4-dione
|